CurrentCareSourcePolicy N/A

Saphnelo (anifrolumab) — Coverage Criteria for Systemic Lupus Erythematosus

Defines medical benefit coverage and prior authorization criteria for Saphnelo (anifrolumab) for adults with active, autoantibody-positive moderate-to-severe systemic lupus erythematosus (SLE) under CareSource.

Policy Summary

PayerCareSource

PolicySaphnelo (anifrolumab) — Coverage Criteria for SLE

Policy CodePolicy N/A

Change TypeOperational revisions to prior authorization and coding

Effective DateJul 1, 2024

Next Review Date

Key ActionObtain prior authorization: ensure member is ≥18, prescribed by/consult with a rheumatologist, documents autoantibody-positive active SLE, and trial of hydroxychloroquine or inability to taper steroids to ≤5 mg prednisone.

SourceLink

POLICY UPDATE CHANGES

Removed requirement for a trial of non-steroid immunosuppressant; now requires trial of hydroxychloroquine or inability to taper steroids instead of both.

Removed SELENA-SLEDAI score from billing/code requirements.

Updated references and clinical guidance citations.

300 mg q4wapproved dosing

6 monthsinitial approval

12 monthsreauthorization

≥18age requirement

Coverage Criteria for Saphnelo (anifrolumab)

Initial therapy

Covered when ALL of the following are met:

Eligibility and baseline requirements: Member is at least 18 years of age; medication prescribed by or in consultation with a rheumatologist; documented diagnosis of active, autoantibody-positive systemic lupus erythematosus (autoantibody positivity defined as a positive ANA titer OR elevated anti-dsDNA OR elevated anti-Sm antibody)age >= 18

From initial authorization criteria

Prior therapy and concurrent therapy: Member has tried and failed hydroxychloroquine OR is unable to reduce chronic glucocorticoid dose to an acceptable level (≤ 5 mg prednisone); standard therapy (e.g., hydroxychloroquine) will be continued unless contraindicatedsteroid <= 5 mg

Operational change: requirement for non-steroid immunosuppressant trial removed; HCQ trial or steroid inability sufficient

Policy Summary

PayerCareSource

PolicySaphnelo (anifrolumab) — Coverage Criteria for SLE

Policy CodePolicy N/A

Change TypeOperational revisions to prior authorization and coding

Effective DateJul 1, 2024

Next Review Date

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Safety and combination use: Member does not have severe active lupus nephritis or severe active central nervous system (CNS) lupus; Saphnelo will not be used concomitantly with other biologic therapies

Dosing and approval duration: Dose: 300 mg IV infusion every 4 weeks (1 vial per 28 days); if all requirements are met, initial approval will be for 6 months

Reauthorization

Reauthorization covered when ALL of the following are met:

Clinical response documentation: Chart notes must document improved disease activity such as reduced number of flares, reduced severity of skin disease, or ability to taper glucocorticoid use

Continuation duration and specialist involvement: Member remains under the care of a rheumatologist; if reauthorization criteria are met, approval will be extended for an additional 12 months

Tolerability and dosing compliance: Member is tolerating therapy without contraindicated adverse effects and dosing has adhered to the approved regimen (300 mg IV every 4 weeks)

CareSource covers Saphnelo (anifrolumab) for adults meeting the criteria in this policy when all coverage requirements are satisfied. Initial approval requires documentation that the member is an adult with active, autoantibody-positive systemic lupus erythematosus (SLE) and that the medication is prescribed by or in consultation with a rheumatologist; dosing is 300 mg IV every 4 weeks with an initial approval of 6 months. Prior authorization is required because Saphnelo is a medical benefit. Use of Saphnelo for indications not listed in this document is not medically necessary; off-label requests should be evaluated under the Off-Label policy.

Use of Saphnelo (anifrolumab) for conditions not specified in this policy is considered not medically necessary. For any indication outside those listed here, providers should refer to the Off-Label policy for coverage determination and submission requirements.

Coding and Billing Information

Coverage/Billing designationmixed

medical

Benefit type: Medical; Saphnelo prior authorization required

Steroid taper threshold (chronic use)

Steroid taper thresholdMember is unable to reduce glucocorticoid dose to an acceptable chronic dose: ≤ 5 mg prednisone (or equivalent) per day

Context in prior therapy requirementThreshold used to determine eligibility when member has not failed hydroxychloroquine — inability to taper to ≤ 5 mg qualifies

Documentation expectationMedical record must document inability to reduce steroid dose to ≤ 5 mg prednisone for chronic use

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required. Saphnelo (anifrolumab) is covered as a medical benefit only with prior authorization. Initial approvals are granted for 6 months when clinical criteria are met. Providers must submit requests to CareSource before infusion.

Benefit type: Medical
Initial approval duration: 6 months when criteria met
Dosage/quantity limit: 300 mg IV every 4 weeks (1 vial per 28 days)

Prior Authorization

Prior Therapy Requirement

Prior therapy requirement. Before initiating Saphnelo, the member must have tried and failed hydroxychloroquine OR be unable to reduce chronic systemic corticosteroid dose to ≤5 mg prednisone (or equivalent).

Required trial: hydroxychloroquine failure OR inability to taper chronic steroid dose to ≤5 mg prednisone
Standard therapy such as hydroxychloroquine should be continued unless contraindicated

Documentation Required

Required Documentation

Documentation required with prior authorization. Requests must include documentation that supports the diagnosis and medical necessity.

Medication prescribed by or in consultation with a rheumatologist
Documentation of active, autoantibody-positive systemic lupus erythematosus (SLE) — at least one of: positive ANA, elevated anti-dsDNA, or elevated anti-Smith (anti-Sm) antibody
Clinical notes confirming diagnosis, prior therapy attempts, and baseline disease activity
For reauthorization: chart notes demonstrating improved disease activity (fewer flares, reduced skin disease severity, or ability to taper glucocorticoids)

Denial Risk

Denial Triggers

Prior authorization denial triggers. Requests will be denied if required criteria or documentation are missing or if exclusion criteria apply.

Member age or benefit ineligibility not met
Medication not prescribed by or in consultation with a rheumatologist
No documentation of autoantibody-positive SLE (no positive ANA, anti-dsDNA, or anti-Sm results)
Lack of required prior therapy information (no trial of hydroxychloroquine and no documentation of inability to taper steroids to ≤5 mg prednisone)
Insufficient clinical notes or missing supporting documentation for diagnosis or prior response
Use in patients with severe active lupus nephritis or severe active central nervous system lupus (not eligible)
Concurrent use with other biologic therapies (not permitted)

Background

Systemic lupus erythematosus (SLE) is a chronic, relapsing autoimmune disease that can cause multisystem inflammation and organ involvement. A substantial proportion of adults with SLE demonstrate increased type I interferon signaling associated with higher disease activity; anifrolumab targets the type I interferon receptor and is indicated for adults with moderate-to-severe SLE in combination with standard therapy. Clinical features commonly include cutaneous involvement, flares of systemic disease activity, and the need for glucocorticoids and background agents such as hydroxychloroquine. Reauthorization decisions require documentation of clinical improvement (for example, fewer flares, reduced skin disease severity, or ability to taper glucocorticoids).

Definitions

IFN-1 (Type I interferon) definition

DefinitionType I interferon (IFN-1) signaling — immune signaling pathway targeted by anifrolumab; increased IFN-1 signaling is observed in a majority of adults with SLE and is associated with higher disease activity

Clinical relevanceSaphnelo is an IFN receptor antagonist that targets IFN-1 signaling for treatment of moderate-to-severe SLE in combination with standard therapy

Epidemiology noteUp to 60–80% of adult SLE patients have increased type I IFN signaling, which correlates with greater disease severity

Autoantibody‑positive SLE — definition

DefinitionAutoantibody-positive SLE — presence of a positive anti‑nuclear antibody (ANA) titer OR elevated (above normal) anti‑double‑stranded DNA (anti‑dsDNA) OR elevated (above normal) anti‑Smith (anti‑Sm) antibody

Authorization requirementAt least one of the listed autoantibody test results must be documented to confirm autoantibody‑positive SLE for coverage consideration

DocumentationProvider must include lab results or chart documentation demonstrating positive ANA or elevated anti‑dsDNA or anti‑Sm